Cancer Treatment and Research Communications · 2020 · 16 citations · 10 references
MedicineOncologyPharmacologyCancer PharmacologyDna RepairMolecular OncologyCancer Precision MedicineDna Damage SignalingGenitourinary Cancer PharmacotherapyProstate CancerTargeted Cancer TherapyDna Repair Gene MutationsGermline MutationsOlaparib TherapyParp InhibitionPoly Adp-ribose Polymerase InhibitorsPoly(adp-ribose) Polymerase InhibitionPoly(adp-ribose) Polymerase InhibitorsRucaparib Therapy
Somatic or germline mutations in genes regulating DNA damage repair have been noted in around 20% of patients with advanced prostate cancer. Poly-ADP-ribose polymerase (PARP) inhibitors have shown encouraging efficacy in prostate cancer patients with DNA repair mutations. Two PARP inhibitors, olaparib, and rucaparib have recently received FDA approval for treatment of patients with advanced castration-resistant prostate cancer (CRPC), while several trials with other PARP inhibitors are ongoing. Here, we briefly summarize the current data supporting the efficacy of PARP inhibitors in advanced CRPC.
10
Olaparib for Metastatic Castration-Resistant Prostate Cancer
Johann S. de Bono, Joaquı́n Mateo, Karim Fizazi et al. · New England Journal of Medicine · 2020 · 2.2K citations · Full text
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
Colin C. Pritchard, Joaquı́n Mateo, Michael F. Walsh et al. · New England Journal of Medicine · 2016 · 1.7K citations · Full text
Life Sciences, Genetics, Oncology +17
Androgen Receptor Signaling Regulates DNA Repair in Prostate Cancers
William R. Polkinghorn, Joel S. Parker, Man X. Lee et al. · Cancer Discovery · 2013 · 567 citations · Full text
Medicine, Cancer Biology, Oncology +17
Elena Castro, Nuria Romero-Laorden, Ángela del Pozo et al. · Journal of Clinical Oncology · 2019 · 372 citations · Full text